BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Status: Open to Accrual

Learn more: 

• https://clinicaltrials.gov/study/NCT05323955

Study Contact: studies@hoosiercancer.org; (317) 921-2050.

Abstracts/Posters/Presentations: 

• S Sammons, A E. D. Van Swearingen, L Noteware, N A. Bagegni, K Moulton, S Threatt, D Jaggers, S Shea, E S. Lipp, E Riley, S Jung, G Broadwater, M Ross, K Strickland, S Beyer, A Conlin, A Morikawa, R Murthy, C K. Anders. Secondary brain metastases prevention after Isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in patients with advanced human epidermal growth factor receptor 2+ breast cancer with the addition of tucatinib (BRIDGET): Hoosier Cancer Research Network BRE21-516 . Poster Presentation, 2023 San Antonio Breast Cancer Symposium. 
• S Sammons, A E. D. Van Swearingen, L Noteware, N A. Bagegni, K Moulton, S Threatt, D Jaggers, S Shea, E S. Lipp, E Riley, S Jung, G Broadwater, M Ross, K Strickland, S Beyer, A Conlin, A Morikawa, R Murthy, C K. Anders. TIPS-19 Trial in Progress: Secondary brain metastases prevention after Isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in patients with advanced human epidermal growth factor receptor 2+ breast cancer with the addition of tucatinib (BRIDGET): Hoosier Cancer Research Network BRE21-516 . Trials in Progress, 2023 SNO/ASCO CNS Cancer Conference. See abstract.